SCHEMBL5033828

SCHEMBL5033828

Cc1nc(-c2ncco2)sc1-c1ccc(C(N)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 5/20 0.44
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
MYC P01106 3/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
MAP4K4 O95819 1/20 0.38
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
CASP3 P42574 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
IKBKB O14920 2/20 0.36
ALOX5 P09917 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5033831 0.83 ALOX5 (0.40) NPC1RAB9AALOX5LMNACYP1A2
SCHEMBL5032076 0.78 MKNK1 (0.44) GPR52MKNK1MKNK2MYCMAP4K4
SCHEMBL5789925 0.77 MKNK2 (0.51) MKNK1MKNK2MYCMAP4K4NPC1
SCHEMBL5032064 0.74 IL2 (0.53) MEN1NPC1RAB9AKMT2ALMNA
SCHEMBL14360767 0.74 LMNA (0.49) MEN1NPC1RAB9AKMT2ALMNA
SCHEMBL5033875 0.74 MCL1 (0.40) MEN1NPC1RAB9AKMT2ALMNA
SCHEMBL8227602 0.72 JAK3 (0.35) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL5029447 0.72 STIM1 (0.44) MEN1NPC1RAB9AKMT2ALMNA
SCHEMBL26638835 0.71 KDM4E (0.54) PIK3CDPIK3CAPIK3CBNPC1RAB9A
SCHEMBL18588590 0.70 ADORA2A (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP claimed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US claimed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO claimed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses NLRP3, CCR1, NLRP1 GPR52 1540/4885MKNK1 3158/4885MKNK2 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.